Fig. 2.

Relationship between biomarkers at the time of ALS diagnosis and disease aggressiveness (n = 526). A NfL in CSF by disease aggressiveness B hs-cTnT in plasma by disease aggressiveness, C Linear regression with CSF NfL levels by D50, D Linear regression with plasma hs-cTnT levels by D50, E Linear regression with CSF NfL by rD50 at the time of sampling, F Linear regression with plasma hs-cTnT by rD50 at the time of sampling. In A and B, median values are indicated as horizontal lines and IQR as error bars, Wilcoxon-Rank-Sum-Test: *** = p < 0.001, * = p < 0.05, ns = non-significant; colors: D50-derived disease aggressiveness, red = high (D50 ≤ 20 months), yellow = intermediate (20 < D50 < 40 months), blue = low aggressive disease (D50 ≥ 40 months)